Sugi Predict

Sugi Predict / Compounds / SCHEMBL10162858

SCHEMBL10162858

SCHEMBL10162858

CC(F)Oc1ccc(CNC(=O)c2cc(C(=O)NCc3ccc4oc(=O)n(C)c4c3)nc3ccnn23)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ CLK1 P49759 2/20 0.38
▸ SMN1; SMN2 Q16637 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ TP53 P04637 5/20 0.37
▸ ADAMTS4 O75173 1/20 0.36
▸ MMP3 P08254 1/20 0.36
▸ MMP8 P22894 1/20 0.36
▸ MMP12 P39900 1/20 0.36
▸ MMP13 P45452 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8225364 0.95 GLS (0.39) HPGDHTTCLK1SMN1; SMN2MAPT
SCHEMBL10162859 0.94 LMNA (0.39) HPGDHTTCLK1SMN1; SMN2MAPT
SCHEMBL10162861 0.90 ALDH1A1 (0.40) HPGDHTTSMN1; SMN2MAPTLMNA
SCHEMBL8225378 0.89 KCNN3 (0.43) HPGDSMN1; SMN2MAPTLMNAKDM4E
SCHEMBL8225958 0.88 TP53 (0.44) SMN1; SMN2MAPTLMNATHRBTP53
SCHEMBL8228916 0.88 METTL3 (0.38) HPGDSMN1; SMN2MAPTLMNAKDM4E
SCHEMBL10162868 0.88 KCNN3 (0.37) HPGDSMN1; SMN2MAPTLMNAKDM4E
SCHEMBL10163504 0.88 MMP13 (0.40) HPGDHTTCLK1SMN1; SMN2MAPT
SCHEMBL8221132 0.88 DHODH (0.39) HPGDMAPTLMNAKDM4EALDH1A1
SCHEMBL8225360 0.88 LMNA (0.41) HPGDHTTSMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 HPGD 313/4885HTT 2315/4885CLK1 2045/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 HPGD 313/4885HTT 2315/4885CLK1 2045/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 HPGD 313/4885HTT 2315/4885CLK1 2045/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 HPGD 313/4885HTT 2315/4885CLK1 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.